The Times of India: March, 2014
Mumbai: The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region — Australia, China, India and Japan is expected to increase moderately over the coming years, climbing from $1.8 billion in 2012 to $2.9 billion by 2019, at a CAGR of 6.3%, forecasts business intelligence provider GBI Research.
According to the company's latest report, Japan and China had the largest shares of the region's NSCLC market in 2012, with 48.5% and 41.5%, respectively. Meanwhile, Australia and India had lower shares of 5.9% and 4.1%.
Sravanthi Addapally, senior analyst GBI Research, says that an aging population and increasing number of NSCLC incident cases, especially in China and India, will be the main drivers behind the anticipated market growth.
"Additionally, the expected launches of premium-priced novel antibodies and immuno therapies in the first and second lines of therapies, targeting both Squamous and Non-Squamous NSCLC patients, will widen the eligible treatment population. This will ultimately maximize the patient share and provide a boost for the market," Addapally says.
At present, the NSCLC pipeline is very strong, with a total of 290 active molecules in development, either as mono therapies or in combination with chemotherapy.